Disease With Market Estimated At $3.9 Billion Lacks Cure – Will This Company Be The First To Find One?

GRI BIO GRI is a dynamic clinical-stage biotechnology company at the forefront of revolutionizing healthcare through groundbreaking scientific advancements. The company is focused on fundamentally changing how inflammatory, fibrotic and autoimmune diseases are treated.

When the body’s immune system is working abnormally, it can lead to chronic inflammation that is extremely damaging. Two of the most recognized inflammatory diseases are IPF, or Idiopathic Pulmonary Fibrosis, and Lupus. IPF currently has no cure and its TAM is estimated to be just shy of $4 billion.

The company has several promising therapies currently in the development pipeline that address these debilitating diseases.

Learn more here:

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.